GLUE

MKT CAP:$1B

Monte Rosa Therapeutics, Inc.

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$20.39+$5.08 (+33.15%)

Apr 24, 2026

Company Details

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develo...

CEO

Markus Warmuth

IPO Date

Jun 24, 2021

Website

www.monterosatx.com

Key Metrics TTM

Revenue

$124M

+63.5% YoY

Net Income

-$39M

EPS (Diluted)

-$0.61

Free Cash Flow

-$27M

Revenue / Share

$1.89

Gross Margin

96.6%

Operating Margin

-43.8%

Net Margin

-31.2%

FCF Margin

-22.2%

P/S

10.5x

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 17, 2026

$124M+63.5%EPS -$0.46

Q4 2025

Mar 17, 2026

$3M-95.4%EPS -$0.70

Q3 2025

Nov 6, 2025

$13M+38.5%EPS -$0.33

Q2 2025

Aug 7, 2025

$23M+394.0%EPS -$0.15

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$24M
Q2 22	$0	$0	-$27M
Q3 22	$0	$0	-$28M
Q4 22	$0	$0	-$32M
Q1 23	$0	$0	-$34M
Q2 23	$0	$0	-$37M
Q3 23	$0	$0	-$37M
Q4 23	$0	$0	-$35M
Q1 24	$1M	-$833.0K	-$35M
Q2 24	$5M	$3M	-$33M
Q3 24	$9M	$9M	-$27M
Q4 24	$61M	$61M	$13M
Q1 25	$85M	$85M	$44M
Q2 25	$23M	$23M	-$16M
Q3 25	$13M	$11M	-$33M
Q4 25	$3M	$693.0K	-$50M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	478.0x	—
Q2 24	56.1x	—
Q3 24	21.7x	—
Q4 24	5.7x	—
Q1 25	2.4x	62.0x
Q2 25	2.1x	15.4x
Q3 25	3.3x	28.8x
Q4 25	10.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$27M	-$29M
Q2 22	-$21M	-$23M
Q3 22	-$21M	-$22M
Q4 22	-$24M	-$31M
Q1 23	-$23M	-$33M
Q2 23	-$25M	-$32M
Q3 23	-$25M	-$26M
Q4 23	$30M	$28M
Q1 24	-$38M	-$40M
Q2 24	-$28M	-$30M
Q3 24	-$21M	-$21M
Q4 24	$129M	$129M
Q1 25	-$45M	-$47M
Q2 25	-$35M	-$36M
Q3 25	$100M	$100M
Q4 25	-$43M	-$44M

Capital Expenditures

Quarter	CapEx
Q1 22	$2M
Q2 22	$3M
Q3 22	$1M
Q4 22	$7M
Q1 23	$9M
Q2 23	$6M
Q3 23	$2M
Q4 23	$2M
Q1 24	$1M
Q2 24	$2M
Q3 24	$399.0K
Q4 24	$183.0K
Q1 25	$2M
Q2 25	$2M
Q3 25	$651.0K
Q4 25	$767.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+111.2%
Q2 22	—	+50.3%
Q3 22	—	+42.8%
Q4 22	—	+38.9%
Q1 23	—	+41.0%
Q2 23	—	+36.7%
Q3 23	—	+30.3%
Q4 23	—	+7.3%
Q1 24	—	+5.1%
Q2 24	—	+0.3%
Q3 24	—	-3.3%
Q4 24	—	+36.7%
Q1 25	+7882.0%	+13.6%
Q2 25	+394.0%	+3.8%
Q3 25	+38.5%	+28.0%
Q4 25	-95.4%	+10.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$3M	—
Q1 23	$0	—
Q2 23	$4M	—
Q3 23	$4M	—
Q4 23	$4M	—
Q1 24	$5M	458.0%
Q2 24	$5M	95.9%
Q3 24	$4M	46.5%
Q4 24	$4M	7.4%
Q1 25	$5M	6.2%
Q2 25	$5M	21.1%
Q3 25	$4M	34.2%
Q4 25	$4M	154.9%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$18M	$6M	—
Q2 22	$21M	$6M	—
Q3 22	$21M	$7M	—
Q4 22	$25M	$8M	—
Q1 23	$27M	$8M	—
Q2 23	$29M	$8M	—
Q3 23	$28M	$9M	—
Q4 23	$27M	$8M	—
Q1 24	$25M	$9M	—
Q2 24	$26M	$9M	—
Q3 24	$28M	$8M	—
Q4 24	$39M	$9M	—
Q1 25	$32M	$9M	—
Q2 25	$31M	$8M	—
Q3 25	$35M	—	$9M
Q4 25	$40M	—	$11M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$138M	$179M	$317M
Q2 22	$104M	$190M	$294M
Q3 22	$112M	$160M	$272M
Q4 22	$55M	$208M	$263M
Q1 23	$52M	$180M	$232M
Q2 23	$47M	$156M	$203M
Q3 23	$59M	$119M	$178M
Q4 23	$128M	$104M	$232M
Q1 24	$100M	$93M	$193M
Q2 24	$109M	$153M	$262M
Q3 24	$126M	$117M	$242M
Q4 24	$224M	$148M	$372M
Q1 25	$79M	$248M	$326M
Q2 25	$69M	$221M	$291M
Q3 25	$208M	$183M	$391M
Q4 25	$130M	$247M	$377M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	47M	+1.3%	+9.5%
Q2 22	47M	+0.2%	+1.5%
Q3 22	47M	+0.1%	+1.6%
Q4 22	49M	+4.6%	+6.3%
Q1 23	49M	+0.9%	+5.9%
Q2 23	49M	+0.2%	+5.9%
Q3 23	50M	+0.8%	+6.6%
Q4 23	57M	+14.3%	+16.4%
Q1 24	60M	+5.7%	+21.9%
Q2 24	71M	+18.4%	+44.1%
Q3 24	82M	+15.1%	+64.6%
Q4 24	61M	-25.1%	+7.9%
Q1 25	83M	+35.0%	+37.9%
Q2 25	82M	-0.9%	+15.4%
Q3 25	82M	+0.3%	+0.5%
Q4 25	66M	-20.5%	+6.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	93
Q2 22	$0	93
Q3 22	$0	93
Q4 22	$0	123
Q1 23	$0	123
Q2 23	$0	123
Q3 23	$0	123
Q4 23	$0	133
Q1 24	$8.0K	133
Q2 24	$35.3K	133
Q3 24	$69.3K	133
Q4 24	$452.6K	134
Q1 25	$633.8K	134
Q2 25	$173.1K	134
Q3 25	$95.3K	134
Q4 25	$14	200K

Revenue / Employee